NEJM Interview: Dr. James Robinson on the aducanumab experience and the structural factors responsible for high drug prices in the United States. - a podcast by The New England Journal of Medicine

Dr. James Robinson is a professor of health economics at the University of California, Berkeley, School of Public Health. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. J.C. Robinson. Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform. N Engl J Med 2021;385:2017-2019.

Further episodes of 301 Moved Permanently

Further podcasts by The New England Journal of Medicine

Website of The New England Journal of Medicine